| TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker EL Mayer, V Abramson, R Jankowitz, C Falkson, PK Marcom, T Traina, ... Annals of Oncology 31 (11), 1518-1525, 2020 | 54 | 2020 |
| A phase II study of pembrolizumab in combination with palliative radiotherapy for hormone receptor-positive metastatic breast cancer R Barroso-Sousa, IE Krop, L Trippa, Z Tan-Wasielewski, T Li, W Osmani, ... Clinical Breast Cancer 20 (3), 238-245, 2020 | 49 | 2020 |
| Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases O Metzger Filho, JP Leone, T Li, Z Tan-Wasielewski, L Trippa, WT Barry, ... Annals of Oncology 31 (9), 1231-1239, 2020 | 35 | 2020 |
| Ribociclib plus trastuzumab in advanced HER2-positive breast cancer: results of a phase 1b/2 trial S Goel, S Pernas, Z Tan-Wasielewski, WT Barry, A Bardia, R Rees, ... Clinical Breast Cancer 19 (6), 399-404, 2019 | 35 | 2019 |
| TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. EL Mayer, VG Abramson, RC Jankowitz, CI Falkson, PK Marcom, ... Journal of Clinical Oncology 37 (15_suppl), 507-507, 2019 | 16 | 2019 |
| Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center K Losk, RA Freedman, A Laws, O Kantor, EA Mittendorf, ... Breast Cancer Research and Treatment 185, 215-227, 2021 | 15 | 2021 |
| Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer EK Lee, Z Tan-Wasielewski, UA Matulonis, MJ Birrer, AA Wright, ... Gynecologic oncology reports 29, 118-122, 2019 | 15 | 2019 |
| Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors T Sella, Y Zheng, Z Tan‐Wasielewski, SM Rosenberg, PD Poorvu, ... Cancer 128 (17), 3158-3169, 2022 | 14 | 2022 |
| Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary … EK Lee, Z Tan-Wasielewski, C Aghajanian, RL Coleman, J Curtis, ... Gynecologic oncology reports 32, 100546, 2020 | 12 | 2020 |
| ‘ADVANCE’(a pilot trial) ADjuVANt chemotherapy in the elderly: developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer RA Freedman, T Li, MS Sedrak, JO Hopkins, N Tayob, MG Faggen, ... Journal of geriatric oncology 14 (1), 101377, 2023 | 5 | 2023 |
| A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). R Barroso-Sousa, IE Krop, L Trippa, Z Tan-Wasielewski, T Li, W Osmani, ... Journal of Clinical Oncology 37 (15_suppl), 1047-1047, 2019 | 4 | 2019 |
| Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center. K Losk, RA Freedman, EA Mittendorf, Z Tan-Wasielewski, L Trippa, ... Journal of Clinical Oncology 37 (15_suppl), 549-549, 2019 | 1 | 2019 |
| Abstract P3-10-08: A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC) TE Keenan, Z Tan-Wasielewski, L Trippa, B Kochupurakkal, JL Guerriero, ... Cancer Research 80 (4_Supplement), P3-10-08-P3-10-08, 2020 | | 2020 |
| Body weight changes in young breast cancer survivors and associated predictors. T Sella, Z Tan-Wasielewski, SM Rosenberg, PD Poorvu, KJ Ruddy, ... Journal of Clinical Oncology 37 (15_suppl), 11574-11574, 2019 | | 2019 |
| 183 Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG) Muaiad Kittaneh, Sunil Badve … L Schwartzberg, T Traina, C Vogel, SM Albeshan, SZ Hossain, ... | | |
| Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations. J Fares, D Kanojia, A Rashidi, AU Ahmed, IV Balyasnikova, MS Lesniak | | |
